KR20030034279A - Antibiotic composition for a diaper - Google Patents
Antibiotic composition for a diaper Download PDFInfo
- Publication number
- KR20030034279A KR20030034279A KR1020010059429A KR20010059429A KR20030034279A KR 20030034279 A KR20030034279 A KR 20030034279A KR 1020010059429 A KR1020010059429 A KR 1020010059429A KR 20010059429 A KR20010059429 A KR 20010059429A KR 20030034279 A KR20030034279 A KR 20030034279A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- ethanol
- sodium lauryl
- lauryl sulfate
- hydrous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
- A61F13/49—Absorbent articles specially adapted to be worn around the waist, e.g. diapers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/44—Devices worn by the patient for reception of urine, faeces, catamenial or other discharge; Portable urination aids; Colostomy devices
- A61F2005/4402—Devices worn by the patient for reception of urine, faeces, catamenial or other discharge; Portable urination aids; Colostomy devices disposable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
- A61F2013/530007—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium being made from pulp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
- A61F2013/530481—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having superabsorbent materials, i.e. highly absorbent polymer gel materials
- A61F2013/530583—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having superabsorbent materials, i.e. highly absorbent polymer gel materials characterized by the form
- A61F2013/530613—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having superabsorbent materials, i.e. highly absorbent polymer gel materials characterized by the form in fibres
- A61F2013/53062—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having superabsorbent materials, i.e. highly absorbent polymer gel materials characterized by the form in fibres being made into a paper or non-woven
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
Abstract
Description
본 발명은 항알러지 , 항염증 및 항균의 기능을 가진 일회용 기저귀 도포용 조성물에 관한 것으로 보다 상세하게는 항알러지 , 항염증 및 항균의 활성을 지니는 마치현 추출물을 함유 또는 마치현 추출물로 처리된 일회용 기저귀에 관한 것이다.The present invention relates to a composition for applying a disposable diaper having the functions of anti-allergic, anti-inflammatory and antibacterial, and more particularly, to a disposable diaper containing or treated with an anti-allergic, anti-inflammatory and antimicrobial activity. It is about.
일반적으로 일회용 기저귀( 유아용, 성인용)는 상면 시이트와 배면 시이트 사이에 우드 펄프와 초흡수성 고분자가 혼합된 흡수체를 포함하는 구조를 가지며 용도에 따라 부가적으로 허리 벤드나 다리 밴드를 갖는다.In general, disposable diapers (for infants and adults) have a structure including an absorber in which wood pulp and superabsorbent polymer are mixed between the top sheet and the back sheet and additionally have a waist bend or leg band depending on the application.
현재 시판중이 기저귀는 통기성이나 착용감 또는 분비물의 흡수성에 치중되어 있으며 기저귀의 착용으로 인한 부작용(예를 들어 기저귀 발진이나 습진)을 없애주거나 이를 줄여주기 위한 제품은 매우 적다.The diapers currently on the market are focused on breathability, fit, or absorbency of secretions, and there are very few products to eliminate or reduce side effects caused by wearing diapers (eg diaper rash or eczema).
따라서 본 발명은 기저귀 제품 자체에 항알러지, 항염증 및 항균 활성이 있는 마치현 추출물로 처리 또는 함유하도록 하여 피부에 항알러지, 항염증 및 항균활성을 나타내도록 하는 일회용 기저귀 도포용 조성물을 제공하는데 있다.Therefore, the present invention is to provide a disposable diaper coating composition for treating or containing anti-allergic, anti-inflammatory and antimicrobial activity in the diaper product itself so as to exhibit anti-allergic, anti-inflammatory and antimicrobial activity on the skin.
본 발명은 일회용 기저귀에 항알러지, 항염 및 항균 활성을 나타내도록 하는 것으로 좀더 상세하게는 일회용 기저귀의 상면 시이트를 마치현(쇠비름)추출물을 이용하여 부직포 중량의 0.5%내지 50% 중량으로 처리하여 항알러지, 항염 및 항균 활성을 나타내는 것을 특징으로 하는 조성물을 제공한다.The present invention is to exhibit anti-allergic, anti-inflammatory and antimicrobial activity in a disposable diaper, more specifically, the anti-allergic by treating the upper sheet of the disposable diaper with 0.5% to 50% of the weight of the nonwoven fabric by using a chorus extract. It provides a composition characterized by exhibiting anti-inflammatory and antibacterial activity.
또한 본 말명에서는 상면 시이트 또는 흡수체에 상기 마치현 추출물을 직접 적용한 일회용 기저귀를 제공한다.In addition, the present invention provides a disposable diaper to which the gusset extract is directly applied to the upper sheet or the absorbent body.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
마치현(쇠비름)은 높이 15~30cm 되는 한해살이 풀이다. 갈적색이고 가지가 많이 갈라져서 비스듬히 옆으로 퍼진다. 여름철에 노란색의 작은 꽃이 가지끝에 3~5개씩 모여 핀다. 전초에 노르아드레날린 C8H11O3N 0.25%와 거의 같은 양의 도파민, 그리고 적은양의 도파가 있다. 또한 칼륨염, 많은 양의 유기산, 강심 배당체 안드라퀴논 배당체, 알카로이드 반응이 있다. (약초의 성분과 이용. 문관심, P227, 1999)March is a year-round grass, 15-30cm high. It is reddish red and many branches are spread diagonally to the side. In summer, small yellow flowers gather at the end of branches. In the outpost, there is almost the same amount of dopamine, and less dopa, as 0.25% of noradrenaline C8H11O3N. There are also potassium salts, large amounts of organic acids, cardiac glycosides andhraquinone glycosides, and alkaloid reactions. (The Ingredients and Uses of Herbs. Interest, P227, 1999)
본 발명의 마치현 추출물을 제조하는 방법은 다음과 같다. 일차로 마치현(쇠비름)을 중량에 대하여 추출 용매로서 물, 에탄올, 메탄올, 프로판올, 부탄올, 아세톤, 에틸아세테이트, 헥산, 벤젠, 클로로포름, 글리세린, 부틸렌글리콜, 프로필렌글리콜, 함수에탄올, 함수메탄올, 함수프로판올, 함수부탄올, 함수글리세린, 함수부틸렌글리콜, 함수프로필렌글리콜로 구성된 그룹으로부터 선택된 하나이상의 용매를 1-20배 부피량을 가한다. 추출 방법으로는 냉각 콘덴서가 장치되어 용매가 증발되는 것을 방지한 상태에서 50-95℃, 4-20시간 가열하여 추출하거나 5-37℃에서 1-15일간 침적시켜 유효성분을 추출하는 방법을 사용할 수 있다. 또한 이렇게 추출한 마치현(쇠비름)추출물을 냉각 콘덴서가 달린 증류장치를 이용하여 감압 농축한 농축액 또는 분말형 마치현(쇠비름)추출물을 제조하거나, 농축액에 β-CD(사이클로 덱스트린), 히드록시프로필-β-CD, 말토-덱스트린, 락토즈, 실리카 분말을 혼합하여 분말형 마치현(쇠비름) 추출물을 제조한다. 위와 같은 방법으로 추출된 마치현 추출물을 부직포에 처리하여 처리된 부직포를 상면 시이트로서 일회용 기저귀에 적용하는데, 부직포 처리시 마치현 추출물을 부직포 중량의 0.5%내지 50% 중량의 양을 사용한다.Machise extract of the present invention is as follows. First, Machi (Sea) is extracted by weight as solvent, water, ethanol, methanol, propanol, butanol, acetone, ethyl acetate, hexane, benzene, chloroform, glycerin, butylene glycol, propylene glycol, hydrous ethanol, hydrous methanol, hydrous 1-20 times by volume of at least one solvent selected from the group consisting of propanol, hydrous butanol, hydrous glycerin, hydrous butylene glycol and hydrous propylene glycol is added. Extraction method is a method of extracting by heating at 50-95 ° C for 4-20 hours or extracting active ingredient at 5-37 ° C for 1-15 days while cooling condenser is installed to prevent evaporation of solvent. Can be. In addition, the extracted Macula (sorbi) extract is concentrated under reduced pressure using a distillation apparatus equipped with a cooling condenser to prepare a concentrate or powdered Maca (sea) extract, or β-CD (cyclodextrin), hydroxypropyl-β- CD, malto-dextrin, lactose, and silica powder were mixed to prepare a powdery portuguese extract. The non-woven fabric treated by treating the gusset extract extracted in the above manner to the nonwoven fabric is applied to the disposable diaper as a top sheet. When the nonwoven fabric is treated, the gusset extract is used in an amount of 0.5% to 50% by weight of the nonwoven fabric.
본 발명에 따르는 일회용기저귀에 사용된 재료는 다음과 같다. 상면 시이트는 폴리프로필렌 부직포를 사용하였으며, 이 시이트를 마치현 추출 용액으로 처리하거나 추출물 파우더로 도포할 수 있다. 흡수체는 우드펄프 또는 초고흡수성 수지로 구성되어 있으며, 이 흡수체를 마치현 추출 용액으로 처리하거나 추출물 파우더로 도포할 수 있다.Materials used in disposable diapers according to the present invention are as follows. The top sheet used a polypropylene nonwoven fabric, which can be treated with a chord extract solution or applied as an extract powder. The absorber is composed of wood pulp or superabsorbent resin, and the absorber can be treated with a chord extract solution or applied as an extract powder.
아래의 실시예는 본 발명의 내용을 설명하나, 본 발명의 내용이 여기에 한정되지는 않는다.The following examples illustrate the content of the invention, but the content of the invention is not limited thereto.
실시예 1.Example 1.
정제수로 세척한 마치현 1kg을 함수 에탄올 6kg에 넣고 추출기로 상온에서6일간 추출한 후 400메쉬 여과포로 여과하고 0.45㎛의 필터로 여과하여 추출액 5.2kg을 얻었다.1 kg of washed Machi strings with purified water was added to 6 kg of brine ethanol, and extracted at room temperature for 6 days with an extractor.
실시예 2-9.Example 2-9.
하기 표 1의 용매를 사용하고 실시예 1과 동일한 방법으로 추출하여 그 결과를 하기 표 1에 기재하였다.Using the solvent of Table 1 below and extracting in the same manner as in Example 1 and the results are shown in Table 1 below.
[표 1]TABLE 1
실시예 10.Example 10.
정제수로 세척한 마치현 1kg을 함수 부틸렌글리콜 6kg에 넣고 냉각 콘덴서가 장치되어 용매가 증발되는 것을 방지한 상태에서 80℃, 3시간 가열한 후 400메쉬 여과포로 여과한 후 0.45㎛의 필터로 여과하여 추출액 5.3kg을 얻었다.1kg of gusset string washed with purified water was put in 6kg of hydrated butylene glycol, and a cooling condenser was installed to prevent evaporation of the solvent, and then heated at 80 ° C. for 3 hours, followed by filtration with 400 mesh filter cloth, followed by filtration with a filter of 0.45 μm. 5.3 kg of extract was obtained.
실시예 11-18.Example 11-18.
하기 표2의 용매를 사용하고 실시예 10과 동일한 방법으로 추출하여 그 결과를 하기 표 2에 기재하였다.Using the solvent of Table 2 below and extracting in the same manner as in Example 10 and the results are shown in Table 2.
[표 2]TABLE 2
실시예 19.Example 19.
정제수로 세척한 마치현 1kg을 함수 에탄올 6kg에 넣고 추출기로 상온에서 6일간 추출한 후 400메쉬 여과포로 여과하고 가온하여 초기 부피의 50%이상 농축한다. 400메쉬 여과포로 여과한 후 0.45㎛의 필터로 여과한다. 여과되어 나온 용액을 냉각 콘덴서가 달린 증류장치를 이용하여 감압 건조시켜 21g의 분말상태의 마치현 추출물을 얻었다1kg of Machihyun washed with purified water was added to 6kg of brine ethanol and extracted with an extractor at room temperature for 6 days, filtered through a 400 mesh filter cloth, and warmed to concentrate more than 50% of the initial volume. Filtration with a 400 mesh filter cloth, followed by a filter of 0.45㎛. The filtered solution was dried under reduced pressure using a distillation apparatus equipped with a cooling condenser to obtain 21 g of a powdered portuguese extract.
실시예 20-29.Example 20-29.
하기 표3의 용매를 사용하고 실시예 19와 동일한 방법으로 추출하여 그 결과를 하기 표 3에 기재하였다.Using the solvent of Table 3 below and extracting in the same manner as in Example 19 and the results are shown in Table 3.
[표 3]TABLE 3
실시예 30.Example 30.
정제수로 세척한 마치현 1kg을 함수에탄올 6kg에 넣고 추출기로 상온에서 6일간 추출한 후 400메쉬 여과포로 여과한 후 0.45㎛의 필터로 여과한다. 가온하여 50%이상 농축한 후, 말토 덱스트린(malto dextrin) 30g과 혼합한 후, 분사 건조시켜 분말상태의 마치현 추출물 46g을 얻었다.1kg of Machihyun washed with purified water was added to 6kg of hydrous ethanol, and extracted at room temperature with an extractor for 6 days, filtered through a 400 mesh filter cloth, and then filtered with a filter of 0.45㎛. After warming and concentrating at 50% or more, the mixture was mixed with 30 g of malto dextrin, and then spray-dried to obtain 46 g of extract of powdered portella.
실시예 31-41.Examples 31-41.
하기 표 4의 용매를 사용하고 실시예 30과 동일한 방법으로 추출하였고, 부형제로는 말토 덱스트린(malto dextrin)을 사용하여 그 결과를 하기 표 4에 기재하였다.The solvent of Table 4 was used and extracted in the same manner as in Example 30, and malto dextrin was used as an excipient and the results are shown in Table 4 below.
[표 4]TABLE 4
실시예 42-52.Examples 42-52.
하기 표 5의 용매를 사용하고 실시예 30과 동일한 방법으로 추출하였고, 부형제로는 β-CD(사이클로덱스트린)을 사용하여 그 결과를 하기 표 5에 기재하였다.The solvent of Table 5 was used and extracted in the same manner as in Example 30, and the results are shown in Table 5 below using β-CD (cyclodextrin) as an excipient.
[표 5]TABLE 5
실시예 53-63.Examples 53-63.
하기 표 6의 용매를 사용하고 실시예 30과 동일한 방법으로 추출하였고, 부형제로는 히드록시프로필-β-CD(사이클로덱스트린)을 사용하여 그 결과를 하기 표 6에 기재하였다.The solvent of Table 6 was used and extracted in the same manner as in Example 30, and the results are shown in Table 6 using hydroxypropyl-β-CD (cyclodextrin) as an excipient.
[표 6]TABLE 6
실시예 64-75.Example 64-75.
하기 표 7의 용매를 사용하고 실시예 30과 동일한 방법으로 추출하였고, 부형제로는 락토즈를 사용하여 그 결과를 하기 표 7에 기재하였다.The solvent of Table 7 was used and extracted in the same manner as in Example 30, and the results are shown in Table 7 using lactose as an excipient.
[표 7]TABLE 7
실시예 76-86.Examples 76-86.
하기 표8의 용매를 사용하고 실시예 30과 동일한 방법으로 추출하였고, 부형제로는 실리카 분말을 사용하여 그 결과를 하기 표 8에 기재하였다.The solvent of Table 8 was used and extracted in the same manner as in Example 30, and the results are shown in Table 8 using silica powder as an excipient.
[표 8]TABLE 8
실험1. 세포독성시험Experiment 1. Cytotoxicity Test
본 추출물에 대한 세포독성을 알아보기 위하여 V79-4세포[Chinase Hamster, CCL (continuous cell line:연속세포주)의 폐조직 섬유아세포]를 배양하여 MTT[3-(4,5- 디메틸타아졸-2-일)-2,5-디페닐테트라졸륨 브로마이드 환원 시험] 법을 수행하고 MTT-포르마잔 생성물을 이소프로필알코올로 추출하여 570nm에서 흡광도를 측정하였다. 각각의 물질에대한 IC50 (저해 농도 50)을 알기 위하여 물질을 배지에 10.0%, 1.0%·로 희석하여 24시간 배양하여 IC50을 구한 결과를 표 9에 나타내었다.In order to examine the cytotoxicity of the extract, cultured V79-4 cells [pulmonary tissue fibroblasts of CCL (continuous cell line), MTT [3- (4,5-dimethyltazol-2] -Yl) -2,5-diphenyltetrazolium bromide reduction test] and the MTT-formazan product was extracted with isopropyl alcohol to measure absorbance at 570 nm. In order to know the IC50 (inhibition concentration 50) for each substance, the substance was diluted in 10.0% and 1.0% in medium and incubated for 24 hours to obtain the IC50.
[표 9] 마치현 추출물의 세포독성 시험결과[Table 9] Cytotoxicity test results of March extract
실험2. 분말상 시료의 세포독성시험Experiment 2. Cytotoxicity Test of Powdered Samples
분말상태의 추출물 0.3g을 100g의 정제수에 녹여 실험 1과 동일한 방법으로 시행하였고 IC50을 구한 결과를 표 10 에 나타내었다.0.3 g of powdered extract was dissolved in 100 g of purified water, and was treated in the same manner as in Experiment 1. The results of obtaining the IC 50 are shown in Table 10.
[표 10] 마치현 추출물의 세포독성 시험결과[Table 10] Cytotoxicity test results of March extract
실험3. 분말상 시료의 세포독성시험Experiment 3. Cytotoxicity Test of Powdered Samples
분말상태의 추출물 0.9g을 100g의 정제수에 녹여 실험 1과 동일한 방법으로시행하였고 IC50을 구한 결과를 표11 에 나타내었다.0.9 g of powdered extract was dissolved in 100 g of purified water and tested in the same manner as in Experiment 1. The results of obtaining the IC 50 are shown in Table 11.
[표 11] 마치현 추출물의 세포독성 시험결과[Table 11] Cytotoxicity test results of Machi Prefecture extract
표 9, 10, 11에서 보는 바와 같이 마치현 추출물은 소듐라우릴설페이트에 비하여 2000배이상 세포독성이 낮게 나타나 안전성이 우수한 추출물임을 확인하였다.As shown in Tables 9, 10 and 11, the gusset extract was more than 2,000 times lower in cytotoxicity than sodium lauryl sulfate, and thus, it was confirmed that the extract was excellent in safety.
실험4. 알러지 평가Experiment 4. Allergy assessment
본 추출물에 대한 알러지 유발여부를 확인하기 위하여 3일 동안 하루 한번씩 시료를 마우스 귀에 25㎕씩 도포하여 4일째 임파절을 떼어내어 임파구를 분리후 5% 이산화탄소 배양기에서 24 - 48시간 배양한 후 증폭정도를 방사선 동위원소 [3H]-메칠티미딘의 삽입량으로 측정한다. 국부임파절평가 (LLNA:local lymph node assay)결과는 대조군에 비해 시료군의 임파구 증폭정도로 나타내며 한 농도에서라도 시료의 증폭정도(S.I:stimulation index)가 3배이상이고 농도별로 증가하는 경향을 보일 경우 알러젠으로 간주하였다.To confirm the allergy to the extract, apply 25 μl of the sample to the mouse ear once a day for 3 days, remove the lymph node on the 4th day, isolate the lymphocytes, and incubate for 24-48 hours in a 5% carbon dioxide incubator. The amount of radioisotope [3 H] -methylthymidine is measured. The local lymph node assay (LLNA) results indicate the lymphocyte amplification of the sample group compared to the control group, and allergens when the amplification degree (SI) of the sample increases more than three times and increases with each concentration even at one concentration. Considered as.
[표 12] 마치현 추출물의 알러지 평가 결과[Table 12] Allergy Evaluation Results of Machi Prefecture Extracts
※- cpm (counter per minute):[3H]-메칠티미딘이 세포 내로 삽입되는 양Cpm (counter per minute): The amount of [3H] -methylthymidine inserted into the cell.
- S.I (stimulation index):시료의 평균 cpm을 대조군의 평균 cpm으로 나눈 값S.I (stimulation index): Average cpm of sample divided by average cpm of control
실험5. 분말상 시료의 알러지 평가Experiment 5. Allergy Assessment of Powdered Samples
분말상태의 추출물 0.3g을 100g의 정제수에 녹여 실험 4와 동일한 방법으로 시행하였고 결과를 표 13 에 나타내었다.0.3 g of powdered extract was dissolved in 100 g of purified water, and was treated in the same manner as in Experiment 4. The results are shown in Table 13.
[표 13] 마치현 추출물의 알러지 평가 결과[Table 13] Allergy Evaluation Results of Machi Prefecture Extracts
실험6. 분말상 시료의 알러지 평가Experiment 6. Allergy Assessment of Powdered Samples
분말상태의 추출물 0.9g을 100g의 정제수에 녹여 실험 4과 동일한 방법으로 시행하였고 결과를 표 14 에 나타내었다.0.9 g of powdered extract was dissolved in 100 g of purified water, and was treated in the same manner as in Experiment 4. The results are shown in Table 14.
[표 14] 마치현 추출물의 알러지 평가 결과[Table 14] Allergy Evaluation Results of Machi Prefecture Extracts
표 12, 13, 14에서 보는 바와 같이 추출물의 증폭정도(S.I)가 3이하로 알러지 유발 가능성이 거의 없는 것으로 나타났다.As shown in Tables 12, 13, and 14, the amplification degree (S.I) of the extract was found to be less than 3 allergic potential.
실험7. 항염증 실험Experiment 7. Anti-inflammatory experiment
본 추출물에 대한 항염증 효과를 알아보기 위하여 마우스 좌측 귀를 대조부위, 우측 귀를 시험부위로 하여 시료를 적용 전 에탄올로 귀를 깨끗하게 세척하고 시료 20㎕를1일1회4일간 지속적으로 도포하고 마지막 도포 1시간 후에 좌측 귀에 에탄올을 우측 귀에는 아라키돈산(Arachidonic acid)을2㎎/ear을 도포하여 1시간 후 귀의부종(ear edema)정도를 마이크로미터로 양쪽 귀를 3회씩 반복 측정하였다.In order to examine the anti-inflammatory effects on the extract, the left ear of the mouse was used as the control site and the right ear as the test site. One hour after the last application, ethanol was applied to the left ear and arachidonic acid (2 mg / ear) was applied to the right ear. After 1 hour, the ear edema was measured three times by micrometer.
항염효과는 아라키돈산 처리군을 기준으로 부종억제 정도로 판정하였으며 그 결과를 표 15에 나타내었다.Anti-inflammatory effect was determined as the degree of edema inhibition based on the arachidonic acid treatment group and the results are shown in Table 15.
[표 15] 국소적용에 의한 귀두께 및 염증억제율[Table 15] Ear thickness and inflammation inhibition rate by topical application
※ 억제율(%) = (A―B) / A × 100※ Inhibition Rate (%) = (A―B) / A × 100
A : 대조군귀의 평균두께(아라키돈산 처리귀의 두께-비처리 귀의두께)A: Average thickness of control ears (thickness of arachidonic acid treated ears-thickness of untreated ears)
B : 시료도포군 귀의두께(시료처리귀의 두께-비처리귀의 두께)B: thickness of the sample-coating group ear (thickness of the sample-treated ear-thickness of the untreated ear)
실험 8. 분말상 시료의 항염증 실험Experiment 8. Anti-inflammatory Experiment of Powdered Sample
분말상태의 추출물 0.3g을 100g의 정제수에 녹여 실험 5과 동일한 방법으로 시행하였고 결과를 표 16 에 나타내었다.0.3 g of powdered extract was dissolved in 100 g of purified water, and was carried out in the same manner as in Experiment 5. The results are shown in Table 16.
[표 16] 국소적용에 의한 귀두께 및 염증억제율[Table 16] Ear thickness and inflammation inhibition rate by topical application
실험 9. 분말상 시료의 항염증 실험Experiment 9. Anti-inflammatory Experiment of Powdered Sample
분말상태의 추출물 0.9g을 100g의 정제수에 녹여 실험 5과 동일한 방법으로 시행하였고 결과를 표 17 에 나타내었다.0.9 g of powdered extract was dissolved in 100 g of purified water, and was treated in the same manner as in Experiment 5. The results are shown in Table 17.
[표 17] 국소적용에 의한 귀두께 및 염증억제율Table 17. Ear thickness and inflammation inhibition rate by topical application
표 15, 16, 17에서 보는바와 같이 마치현 추출물 높은 염증억제율을 보였으며 부종 증가율 유의차 검증시 마치현 추출물은 아라키돈산과 99%의 유의수준을 보였다.As shown in Tables 15, 16, and 17, the gut extract showed high anti-inflammatory inhibition rate, and the machi extract showed a 99% significance level with arachidonic acid.
실험10. 피부1차 자극성시험(폐쇄첩포실험)Experiment 10. Skin primary irritation test (closed patch test)
본 추출물1.0%, 3.0% 수용액 및 소듐라우릴설페이트 0.08% 수용액을 건강한 성인 남,여 50명을 대상으로 등 부위에 각 시료의 일정량(0.2g)을 24시간 첩포한 후 핀 챔버를 제거하고 4시간 경과한 다음 육안으로 피부상태 변화를 판독하여 그 결과를 표 18에 나타내었다.After extracting 1.0%, 3.0% aqueous solution and 0.08% aqueous solution of sodium lauryl sulfate in a healthy adult male and female, a certain amount (0.2 g) of each sample was applied to the back area for 24 hours, and then the pin chamber was removed. After the passage of time, the skin condition was visually read and the results are shown in Table 18.
[표 18] 피부1차 자극성 시험결과[Table 18] Result of primary skin irritation test
※ 판정기준 - ; 홍반이나 특이한 현상없음※ Criteria - ; No erythema or unusual symptoms
+- ; 주위보다 약간붉어짐+-; Slightly redder than the surroundings
+ ; 주위보다 현저히 붉어짐+; Significantly redder than the surroundings
++ ; 주위보다 심하게 붉어지고 부풀어오름++; Severe redness and swelling than the surroundings
{(+-)수×1} + {(+)수×02} + {(++)수×3}{(+-) Number × 1} + {(+) number × 02} + {(++) number × 3}
자극도=-----------------------------------------Stimulation degree = -----------------------------------------
피시험자수Number of test subjects
실험11. 분말상 시료의 피부1차 자극성시험(폐쇄첩포실험)Experiment 11. Primary skin irritation test of powdered sample (closed patch test)
분말상태의 추출물 0.3g을 100g의 정제수에 녹여 실험 5과 동일한 방법으로시행하였고 결과를 표 19 에 나타내었다.0.3 g of the powdered extract was dissolved in 100 g of purified water, and was carried out in the same manner as in Experiment 5. The results are shown in Table 19.
[표 19] 피부1차 자극성 시험결과[Table 19] Result of primary skin irritation test
실험12. 분말상 시료의 피부1차 자극성시험(폐쇄첩포실험)Experiment 12. Primary skin irritation test of powdered sample (closed patch test)
분말상태의 추출물 0.9g을 100g의 정제수에 녹여 실험 5와 동일한 방법으로 시행하였고 결과를 표 20 에 나타내었다.0.9 g of powdered extract was dissolved in 100 g of purified water, and was carried out in the same manner as in Experiment 5. The results are shown in Table 20.
[표 20] 피부1차 자극성 시험결과Table 20 Skin primary irritation test results
실험13. 항균시험Experiment 13. Antibacterial test
항균성 실험은 종이 디스크를 이용한 한천 확산(agar diffusion)법으로 측정하였다. 균주들을 액체배지 100㎖에 한 백금이를 접종하여 적==정온도에서 18~24시간 배양하여 활성화 시킨다. 그 액을 Top agar(0.75% agar)에 100㎕접종(107~108cfu/㎖)하여 플래이트 위에 덮고 각 추출물을 멸균된 디스크에 20㎕씩 건조시켜 플래이트 표면 위에 올려놓았다. 36시간 배양하여 disc 주위에 생성된 저해환의 직경(㎜)으로 항균력을 측정하였다.Antimicrobial experiments were measured by agar diffusion using a paper disk. Inoculate strains into 100 ml of liquid medium and incubate them for 18 to 24 hours at red = = constant temperature to activate them. The solution was inoculated into the top agar (0.75% agar) by 100 µl (107-108 cfu / ml) and covered on the plate. Each extract was dried on sterile disks and dried on 20 µl. After 36 hours of incubation, the antimicrobial activity was measured by the diameter of the inhibitory rings formed around the disc (mm).
사용균주 및 배지Use strain and medium
다음과 같은 미생물 공시균주로 사용하였다. Escherichia Coli , Staphylococcus aureus, Bacillus subtilis, candida albican 선택하였다. 균의 생육배지는 Trypticase soy agar(Difco) 를 사용하였다.It was used as the microbial test strain as follows. Escherichia Coli, Staphylococcus aureus, Bacillus subtilis, and candida albican were selected. The growth medium of the bacteria was used Trypticase soy agar (Difco).
실험 결과는 표 21에 나타내었다.The experimental results are shown in Table 21.
[표 21] 항균시험결과[Table 21] Antibacterial test results
실험14. 분말상 시료의 항균 testExperiment 14. Antibacterial Test of Powdered Samples
분말상태의 추출물 1.0g을 99g의 정제수에 녹여 실험 14와 동일한 방법으로 시행하였고 실험 결과는 표 22에 나타내었다.1.0 g of powdered extract was dissolved in 99 g of purified water, and the experiment was performed in the same manner as in Experiment 14. The results are shown in Table 22.
[표 22] 분말상 시료의 항균시험결과[Table 22] Antibacterial test results of powdered samples
실험15. 분말상 시료의 항균 testExperiment 15. Antibacterial Test of Powdered Samples
분말상태의 추출물 2.0g을 98g의 정제수에 녹여 실험 14와 동일한 방법으로 시행하였고 실험 결과는 표 23에 나타내었다.2.0 g of powdered extract was dissolved in 98 g of purified water, and was carried out in the same manner as in Experiment 14. The experimental results are shown in Table 23.
[표 23] 분말상 시료의 항균시험결과[Table 23] Antibacterial test results of powdered samples
적용예 1. 마치현 추출물을 이용한 상면 시이트의 처리Application Example 1. Treatment of upper sheet using gusset extract
실시예 1-18의 방법으로 추출한 마치현 추출물을 폴리올레핀(예를 들어 폴리프로필렌) 섬유에 약 5-50% 중량으로 코팅한 후 카팅 및 열접착 공정을거처 마치현으로 코팅된 부직포를 제조하였다.The gusset extract extracted by the method of Example 1-18 was coated with a polyolefin (eg polypropylene) fiber at about 5-50% by weight to prepare a nonwoven fabric coated with a gusset through a carding and heat bonding process.
적용예 2. 분말상의 마치현 추출물을 이용한 상면 시이트의 처리Application Example 2 Treatment of Top Sheet Using Powdery Macchi Extract
실시예 19-87의 방법으로 추출한 분말상의 마치현 추출물을 아세트산 1.5%(w/w)을 함유한 수용액을 이용하여 5%(w/w)가 되게 산성 수용액을 제조하고 이를 이용하여 폴리올레핀 섬유에 약 5-50% 중량으로 코팅한 후 카팅 및 열접착 공정을 거처 마치현으로 코팅된 부직포를 제조 하였다.An acidic aqueous solution was prepared in 5% (w / w) by using an aqueous solution containing 1.5% (w / w) of acetic acid, and the powdery gusset extract extracted by the method of Example 19-87 was used for the polyolefin fiber. After coating at 5-50% by weight, a non-woven fabric was coated with a gusset string through a carding and heat bonding process.
적용예 3 . 마치현 추출물을 이용한 흡수체의 제조Application Example 3. Preparation of Absorbent Using Machi Prefecture Extract
실시예 1-18의 방법으로 추출한 마치현 추출물을 우드펄프의 중량에 대해 1-50% 중량으로 혼합하여 흡수체를 제조하였다.An extract was prepared by mixing 1-50% by weight of the Portuguese extract extracted by the method of Example 1-18 with respect to the weight of the wood pulp.
적용예 4. 분말상의 마치현 추출물을 이용한 흡수체의 제조Application Example 4. Preparation of absorber using powdery gusset extract
실시예 19-87의 방법으로 추출한 분말상의 마치현 추출물을 우드펄프의 중량에 대해 1-50% 중량으로 혼합하여 흡수체를 제조하였다.A powdery gusset extract extracted by the method of Example 19-87 was mixed at a weight of 1-50% with respect to the weight of the wood pulp to prepare an absorbent body.
적용예 5. 일회용 기저귀의 제조Application Example 5. Fabrication of Disposable Diapers
적용예 1-4의 방법으로 제조된 상면 시이트 및/또는 흡수체를 사용하여 통상적인 기저귀 제조 공정을 거처 본 발명에 따른 일회용 기저귀를 제조하였다.Disposable diapers according to the present invention were produced by a conventional diaper manufacturing process using the top sheet and / or absorber prepared by the method of Application Examples 1-4.
본 발명의 일회용 기저귀 도포용 조성물은 항알러지, 항염증 및 항균 활성이 있는 마치현 추출물을 함유하여 피부에 항알러지, 항염증 및 항균활성을 나타낸다.Disposable diaper coating composition of the present invention contains an anti-allergic, anti-inflammatory and antimicrobial activity of Machi Prefecture exhibits anti-allergic, anti-inflammatory and antimicrobial activity on the skin.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010059429A KR20030034279A (en) | 2001-09-25 | 2001-09-25 | Antibiotic composition for a diaper |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010059429A KR20030034279A (en) | 2001-09-25 | 2001-09-25 | Antibiotic composition for a diaper |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20030034279A true KR20030034279A (en) | 2003-05-09 |
Family
ID=29562211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020010059429A KR20030034279A (en) | 2001-09-25 | 2001-09-25 | Antibiotic composition for a diaper |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20030034279A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100887619B1 (en) * | 2007-05-04 | 2009-03-12 | 그린텍이십일 주식회사 | Composition for inhibiting a diaper rash and disposable absorbent article containing the same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010004857A (en) * | 1999-06-30 | 2001-01-15 | 배지현 | Portulaca oleracea l. extract |
KR20010015270A (en) * | 1999-07-13 | 2001-02-26 | 안득훈 | Herb medicine composition to be spreaded on diper for prevention of eruption |
KR20010077652A (en) * | 2000-02-07 | 2001-08-20 | 정찬복 | Compositions for whitening cosmetics |
KR20020013675A (en) * | 2000-08-14 | 2002-02-21 | 김윤사 | Antibiotic and cosmetic compositions containing herb medicines |
-
2001
- 2001-09-25 KR KR1020010059429A patent/KR20030034279A/en active Search and Examination
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010004857A (en) * | 1999-06-30 | 2001-01-15 | 배지현 | Portulaca oleracea l. extract |
KR20010015270A (en) * | 1999-07-13 | 2001-02-26 | 안득훈 | Herb medicine composition to be spreaded on diper for prevention of eruption |
KR20010077652A (en) * | 2000-02-07 | 2001-08-20 | 정찬복 | Compositions for whitening cosmetics |
KR20020013675A (en) * | 2000-08-14 | 2002-02-21 | 김윤사 | Antibiotic and cosmetic compositions containing herb medicines |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100887619B1 (en) * | 2007-05-04 | 2009-03-12 | 그린텍이십일 주식회사 | Composition for inhibiting a diaper rash and disposable absorbent article containing the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101909586A (en) | External skin preparation for pimpled skin | |
CN106727097A (en) | A kind of natural cosmetics anticorrosive composite with strong effect wide-spectrum bacteriostatic activity | |
CN109745514A (en) | A kind of composition and its preparation method and application with anti-bacteria and anti-virus | |
CN113081928A (en) | Plant bacteriostatic gel and preparation method and application thereof | |
CN115252509B (en) | Camelina sativa extract used as raw material of whitening antibacterial cosmetics, and preparation method and application thereof | |
KR102148808B1 (en) | Feminine Cleanser Composition Comprising Natural Antimicrobial Agents | |
KR20160048550A (en) | Phellodendri cortex active ingredient extraction method and functional hygiene articles comprising phellodendri cortex active ingredient extraction using the same | |
KR20080011847A (en) | Natural antibiotic and method of manufacturing the same | |
KR20020076375A (en) | Cosmetics Useful for atopic skin | |
JPH09158042A (en) | Textile treating agent | |
KR100770140B1 (en) | A Composition for Wet Tissue | |
KR100915711B1 (en) | Moisturizing, anti-inflammatory, antibacterial or anti-allergic compositions, and preparation methods thereof | |
KR101717020B1 (en) | The composition comprising saponins derived from green tea seed having antifungal and anticancer activity and manufacturing method thereof | |
CN105943430A (en) | Cosmetic composition having function of removing acne | |
KR20030034279A (en) | Antibiotic composition for a diaper | |
CN101897693B (en) | Catechin compounds or application of plant extraction containing same and pharmaceutical composition | |
WO2019009663A1 (en) | Composition for preventing and ameliorating athlete's foot | |
Sumathy et al. | Evaluation of antioxidant and antimicrobial activity of flavanoid rich fraction of two Indian medicinal plants | |
CN113142204A (en) | Application of honokiol in preparation of bactericide for preventing and treating plant diseases caused by downy mildew | |
KR20090046387A (en) | Functional cosmetic composition comprising scutellaria,houttuynia,artemisia,citurs junos extract having antimicrobial activity | |
Nayak et al. | Antibacterial potency of hydro-alcohol leaf extract of Morinda citrifolia L.(Noni) by soxhlet extraction method | |
KR100562077B1 (en) | Method for manufacturing Punica granatum L. extract having antibacterial property and antibacterial compositions for dermatologically external preparation containing Punica granatum L. extract manufactured by the above method | |
KR20180006551A (en) | Antimircrobial Composition Including a Extract Derived from Torreya nucifera | |
KR101900090B1 (en) | Composition comprising of plant extract for hygienic band having antimicrobial activity and hygienic band using the same | |
KR20050024159A (en) | Cosmetic composition comprising mixture extracts of Oryza sativa L., Glycine max. MERR, Sesamum indicum L., Leonurus sibiricus L., Acorus calamus var., Prunus persica Betsch and Portulaca oleracea L. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20040930 Effective date: 20050929 |